(INGR) Ingredion - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4571871023

Sweeteners, Starches, Nutrition Ingredients, Biomaterials, Corn Oil

INGR EPS (Earnings per Share)

EPS (Earnings per Share) of INGR over the last years for every Quarter: "2020-09": 1.77, "2020-12": 1.75, "2021-03": 1.85, "2021-06": 2.05, "2021-09": 1.67, "2021-12": 1.09, "2022-03": 1.95, "2022-06": 2.12, "2022-09": 1.73, "2022-12": 1.65, "2023-03": 2.8, "2023-06": 2.32, "2023-09": 2.33, "2023-12": 1.97, "2024-03": 2.08, "2024-06": 2.87, "2024-09": 3.05, "2024-12": 2.63, "2025-03": 2.97, "2025-06": 2.87, "2025-09": 0,

INGR Revenue

Revenue of INGR over the last years for every Quarter: 2020-09: 1502, 2020-12: 1593, 2021-03: 1614, 2021-06: 1762, 2021-09: 1763, 2021-12: 1755, 2022-03: 1892, 2022-06: 2044, 2022-09: 2023, 2022-12: 1987, 2023-03: 2137, 2023-06: 2069, 2023-09: 2033, 2023-12: 1921, 2024-03: 1882, 2024-06: 1878, 2024-09: 1870, 2024-12: 1800, 2025-03: 1813, 2025-06: 1833, 2025-09: null,

Description: INGR Ingredion

Ingredion Incorporated is a leading global manufacturer and supplier of sweeteners, starches, and nutrition ingredients derived from corn and other starch-based materials. The companys diverse product portfolio caters to a wide range of industries, including food and beverages, paper, textiles, pharmaceuticals, and biomaterials.

Key Performance Indicators (KPIs) that can be used to evaluate Ingredions performance include revenue growth, gross margin expansion, and return on equity (RoE). With a RoE of 16.11%, the company demonstrates a strong ability to generate profits from shareholder equity. Additionally, the companys diversified product offerings and global presence provide a stable foundation for long-term growth.

Ingredions product segments, including sweeteners, starches, and nutrition ingredients, are used in various applications, such as food and beverage production, paper manufacturing, and pharmaceuticals. The companys ability to innovate and expand its product offerings in emerging markets, such as biomaterials, can drive future growth. Key metrics to monitor include the companys revenue mix, with a focus on higher-margin products, and its ability to maintain pricing power in a competitive market.

From a valuation perspective, Ingredions price-to-earnings (P/E) ratio of 14.18 and forward P/E of 12.30 suggest a relatively attractive valuation compared to its earnings growth prospects. Investors should monitor the companys earnings growth trajectory, as well as its ability to maintain a stable dividend payout, to assess the stocks potential for long-term returns.

INGR Stock Overview

Market Cap in USD 7,706m
Sub-Industry Agricultural Products & Services
IPO / Inception 1997-12-11

INGR Stock Ratings

Growth Rating 31.4%
Fundamental 64.1%
Dividend Rating 52.5%
Return 12m vs S&P 500 -21.0%
Analyst Rating 3.43 of 5

INGR Dividends

Dividend Yield 12m 2.68%
Yield on Cost 5y 4.83%
Annual Growth 5y -1.82%
Payout Consistency 97.7%
Payout Ratio 28.0%

INGR Growth Ratios

Growth Correlation 3m -80.4%
Growth Correlation 12m -52.9%
Growth Correlation 5y 92.4%
CAGR 5y 15.02%
CAGR/Max DD 3y (Calmar Ratio) 0.72
CAGR/Mean DD 3y (Pain Ratio) 2.22
Sharpe Ratio 12m 0.08
Alpha -22.03
Beta 0.735
Volatility 17.52%
Current Volume 399.1k
Average Volume 20d 532.1k
Stop Loss 116.5 (-3.1%)
Signal -0.75

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (676.0m TTM) > 0 and > 6% of Revenue (6% = 439.0m TTM)
FCFTA 0.10 (>2.0%) and ΔFCFTA -3.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 30.80% (prev 24.23%; Δ 6.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.15 (>3.0%) and CFO 1.18b > Net Income 676.0m (YES >=105%, WARN >=100%)
Net Debt (926.0m) to EBITDA (1.20b) ratio: 0.77 <= 3.0 (WARN <= 3.5)
Current Ratio 2.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (65.6m) change vs 12m ago -1.80% (target <= -2.0% for YES)
Gross Margin 25.57% (prev 21.83%; Δ 3.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 97.53% (prev 106.8%; Δ -9.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 31.68 (EBITDA TTM 1.20b / Interest Expense TTM 31.0m) >= 6 (WARN >= 3)

Altman Z'' 6.36

(A) 0.29 = (Total Current Assets 3.52b - Total Current Liabilities 1.26b) / Total Assets 7.78b
(B) 0.69 = Retained Earnings (Balance) 5.38b / Total Assets 7.78b
(C) 0.13 = EBIT TTM 982.0m / Avg Total Assets 7.50b
(D) 1.26 = Book Value of Equity 4.43b / Total Liabilities 3.50b
Total Rating: 6.36 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 64.06

1. Piotroski 6.50pt = 1.50
2. FCF Yield 9.31% = 4.66
3. FCF Margin 10.98% = 2.74
4. Debt/Equity 0.42 = 2.41
5. Debt/Ebitda 0.77 = 2.05
6. ROIC - WACC (= 5.67)% = 7.09
7. RoE 16.76% = 1.40
8. Rev. Trend -86.91% = -6.52
9. EPS Trend -25.40% = -1.27

What is the price of INGR shares?

As of October 22, 2025, the stock is trading at USD 120.17 with a total of 399,064 shares traded.
Over the past week, the price has changed by -0.61%, over one month by -0.91%, over three months by -9.08% and over the past year by -8.06%.

Is Ingredion a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Ingredion is currently (October 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 64.06 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INGR is around 116.12 USD . This means that INGR is currently overvalued and has a potential downside of -3.37%.

Is INGR a buy, sell or hold?

Ingredion has received a consensus analysts rating of 3.43. Therefor, it is recommend to hold INGR.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the INGR price?

Issuer Target Up/Down from current
Wallstreet Target Price 146.3 21.8%
Analysts Target Price 146.3 21.8%
ValueRay Target Price 127.9 6.5%

Last update: 2025-10-15 03:49

INGR Fundamental Data Overview

Market Cap USD = 7.71b (7.71b USD * 1.0 USD.USD)
P/E Trailing = 11.7246
P/E Forward = 10.0503
P/S = 1.0532
P/B = 1.807
P/EG = 1.3311
Beta = 0.735
Revenue TTM = 7.32b USD
EBIT TTM = 982.0m USD
EBITDA TTM = 1.20b USD
Long Term Debt = 1.74b USD (from longTermDebt, last quarter)
Short Term Debt = 46.0m USD (from shortTermDebt, last quarter)
Debt = 1.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 926.0m USD (from netDebt column, last quarter)
Enterprise Value = 8.62b USD (7.71b + Debt 1.79b - CCE 868.0m)
Interest Coverage Ratio = 31.68 (Ebit TTM 982.0m / Interest Expense TTM 31.0m)
FCF Yield = 9.31% (FCF TTM 803.0m / Enterprise Value 8.62b)
FCF Margin = 10.98% (FCF TTM 803.0m / Revenue TTM 7.32b)
Net Margin = 9.24% (Net Income TTM 676.0m / Revenue TTM 7.32b)
Gross Margin = 25.57% ((Revenue TTM 7.32b - Cost of Revenue TTM 5.45b) / Revenue TTM)
Gross Margin QoQ = 26.02% (prev 25.70%)
Tobins Q-Ratio = 1.11 (Enterprise Value 8.62b / Total Assets 7.78b)
Interest Expense / Debt = 0.67% (Interest Expense 12.0m / Debt 1.79b)
Taxrate = 23.55% (61.0m / 259.0m)
NOPAT = 750.7m (EBIT 982.0m * (1 - 23.55%))
Current Ratio = 2.78 (Total Current Assets 3.52b / Total Current Liabilities 1.26b)
Debt / Equity = 0.42 (Debt 1.79b / totalStockholderEquity, last quarter 4.25b)
Debt / EBITDA = 0.77 (Net Debt 926.0m / EBITDA 1.20b)
Debt / FCF = 1.15 (Net Debt 926.0m / FCF TTM 803.0m)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.69% (Net Income 676.0m / Total Assets 7.78b)
RoE = 16.76% (Net Income TTM 676.0m / Total Stockholder Equity 4.03b)
RoCE = 17.01% (EBIT 982.0m / Capital Employed (Equity 4.03b + L.T.Debt 1.74b))
RoIC = 12.85% (NOPAT 750.7m / Invested Capital 5.84b)
WACC = 7.18% (E(7.71b)/V(9.49b) * Re(8.72%) + D(1.79b)/V(9.49b) * Rd(0.67%) * (1-Tc(0.24)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.60%
[DCF Debug] Terminal Value 67.45% ; FCFE base≈888.6m ; Y1≈583.4m ; Y5≈266.8m
Fair Price DCF = 73.06 (DCF Value 4.69b / Shares Outstanding 64.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -25.40 | EPS CAGR: -52.29% | SUE: -4.0 | # QB: 0
Revenue Correlation: -86.91 | Revenue CAGR: -3.52% | SUE: -1.55 | # QB: 0

Additional Sources for INGR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle